Abstract: Disclosed are methods for treating a patient suffering from (i) a cognitive, neurological or psychological disease or disorder; and (ii) a sleep disorder comprising the step of administering to said patient a therapeutically effective amount of an N-Methyl-D-aspartic acid (NMDA) receptor partial agonist, in particular rapastinel or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.

Abstract: Disclosed are methods for treating a patient suffering from (i) a cognitive, neurological or psychological disease or disorder; and (ii) a sleep disorder comprising the step of administering to said patient a therapeutically effective amount of an N-Methyl-D-aspartic acid (NMDA) receptor partial agonist, in particular rapastinel or a pharmaceutically acceptable salt, ester, prodrug or metabolite thereof.

Abstract: Disclosed are methods for treating a cognitive or neurological diseases and disorders comprising the step of administering rapastinel or a pharmaceutically acceptable salt, ester or metabolite thereof to a patient in need thereof, wherein rapastinel is administered for an administration period of about one to about fourteen days followed by a holiday period of at least about one to sixteen weeks wherein rapastinel is not administered.

Abstract: The present invention relates to methods for treating central nervous system disorders, such as Alzheimer's disease, anxiety and major depressive disorder, by administering piperidine derivatives, e.g., 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof.

Abstract: The present invention relates to methods for treating central nervous system disorders, such as Alzheimer's disease, anxiety and major depressive disorder, by administering piperidine derivatives, e.g., 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof.

Abstract: An approach for propagating changes from a database to a client includes providing to the client a copy of a portion of the database, wherein the portion of the database contains a first data item. An updated value of the first data item is generated that reflects the application of a plurality of changes to the first data item. The updated value of the first data item is provided to the client with operator data that indicates one or more operations to be performed to update the copy of the portion of the database at the client with the updated value of the first data item. As used herein, the term “data item” may refer to any type of data. For example, in the context of database systems, a data item may be an individual value, a database record containing several values, e.g., a row, a database table, or a group of database tables.

Abstract: The present invention provides a method for the treatment of individuals diagnosed with a childhood behavioral disorder such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) by administering an effective amount of memantine.

Abstract: The invention relates to the use of NMDA receptor antagonists such as 1-aminocyclohexane derivatives to modify deposition of potentially toxic and fibrillogenic A? peptides in amyloidopathies. Specifically, the invention relates to the ability of memantine to intervene in the processing of APP and decrease the levels of fibrillogenic A? peptides.